CombinatoRx (ZALICUS) teams up with Novartis May 6, 2009 08:04
CombinatoRx Inc. announced an oncology collaboration with Novartis AG, the Swiss drug giant, that will yield CombinatoRx an up-front payment of $4 million.
CombinatoRx is headquartered in Cambridge, where Novartis has a global research unit. A Globe story from last fall noted that Novartis has roughly 2,000 employees in Cambridge.
"The collaboration will explore combination effects in cell lines representing a broad spectrum of cancers to provide a robust and systematic understanding of combination therapy opportunities," CombinatoRx said in a press release.
The release added: "Under the agreement, CombinatoRx will receive a $4 million up-front payment and funding for research support for two years. In addition, for each combination advanced to the market from the collaboration, CombinatoRx is eligible to receive up to $58 million in clinical, regulatory, and commercial milestones."
Alexis Borisy, president and chief executive of CombinatoRx, said in a statement, "Our alliance with Novartis further supports our business strategy of leveraging the CombinatoRx drug discovery platform while retaining important product rights."
Market Data 
Markets 
AI
